Drugs / Xevinapant
Trials 18 · a red edge is where a trial was stopped
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xevinapant | “A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer” NCT06145412 ↗ |
| Known as | AT-406 | “compound Debio 1143 (AT-406), a small molecule second mitochondria-derived activator of caspase C (Smac) mimetic” NCT01078649 ↗ |
| Known as | D-1143 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2158051 ↗ |
| Known as | DEBIO1143 | “Debio 1143 is an investigational, oral monovalent second mitochondrial-derived activator of caspases (SMAC) mimetic designed to promote programmed cell death (apoptosis) in...” NCT03871959 ↗10“PURPOSE: To assess safety/tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of DEBIO1143, an antagonist of inhibitor apoptosis proteins.” PMID 25716544 ↗ Feb 2015 “Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.” NCT01930292 ↗ “Xevinapant (Debio 1143) administrated as oral solution from Day 1 to 14, every 21-day cycle.” NCT04459715 ↗ “Xevinapant (Debio 1143)” NCT05519540 ↗ “Drug: DEBIO1143” NCT03871959 ↗ |
| Known as | IAP INHIBITOR AT-406 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2158051 ↗ |
| Known as | MSC2735845A | ChEMBL registry synonym — accepted as the source's own label CHEMBL2158051 ↗ |
| Known as | SM-406 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2158051 ↗ |
| Action | Inhibit | “inhibiting XIAP (X linked IAP)” NCT01078649 ↗ |
| Modality | Small molecule | “a small molecule second mitochondria-derived activator of caspase C (Smac) mimetic” NCT01078649 ↗ |
| Route | Oral | “when administered orally” NCT01078649 ↗ |
| Target | XIAP | “inhibiting XIAP (X linked IAP)” NCT01078649 ↗ |